JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Brian Poff, the Executive Vice President and Chief Financial Officer of Addus HomeCare Corp (NASDAQ:ADUS), recently sold 2,304 shares of the company’s common stock. The sale comes as InvestingPro data shows the stock has declined nearly 15% in the past week, with the company currently trading at a P/E ratio of 22.8x. The sale, executed on February 25, was part of a pre-established trading plan and was aimed at covering tax obligations from vested restricted stock awards. The shares were sold at a weighted average price of $99.88, generating a total of $230,123. Following this transaction, Poff retains ownership of 32,969 shares in the company. According to InvestingPro analysis, Addus HomeCare maintains strong financial health with a moderate debt level and sufficient cash flows to cover interest payments. The company’s market capitalization stands at $1.73 billion, with analysts maintaining a bullish outlook despite recent price weakness. For deeper insights into ADUS’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Addus HomeCare reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $1.38 and revenue of $297.1 million, both exceeding analyst forecasts. The company also highlighted a 9.1% increase in full-year revenue, reaching $1.2 billion, alongside a notable acquisition of Gentiva. KeyBanc Capital Markets maintained an Overweight rating on Addus HomeCare, citing strong performance in its Personal Care segment and the positive impact of the Gentiva acquisition. However, they noted concerns about potential Medicaid policy changes, although Addus HomeCare’s management assured investors of the company’s resilience to such shifts.
Stephens adjusted its price target for Addus HomeCare to $142 while maintaining an Overweight rating, emphasizing the company’s commitment to a 10% annual revenue growth strategy. They highlighted Addus HomeCare’s focus on mergers and acquisitions, despite the legislative uncertainties surrounding Medicaid reforms. Raymond (NSE:RYMD) James also adjusted its price target to $120 from $140, keeping an Outperform rating, and noted the company’s strong cash flow and balance sheet as strengths amid Medicaid-related concerns.
Despite these positive earnings results and analyst support, Addus HomeCare’s stock experienced a decline, reflecting investor apprehension about potential Medicaid cuts. The company remains optimistic about its strategic growth through acquisitions and its ability to navigate the current healthcare policy environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.